Abstract The aim of this study was to assess the clinical value of preoperative blood levels of
HE4 as a predictor of overall survival in patients with ovarian cancer and to validate previous …

Objective This study aimed to assess the clinical importance of various biomarkers,
including NLR, CEA, CA199, CA125, CA153, and HE4, through dynamic testing to evaluate …

Clinical utility of new biomarkers often requires the identification of their optimal threshold.
This external validation study was conducted to assess the performance of the preoperative …

Background The aim of this study is to evaluate a new tumour marker, HE4, and to compare
it with CA125 in predicting optimal cytoreduction and response to chemotherapy. Thirty …

Actually, in literature there are not valid tools able to predict the chemotherapy response
during first-line ovarian cancer treatment. CA125 and human epididymis protein 4 (HE4) …

Objectives To assess the clinical value of early clearance of HE4 and CA125 for platinum
sensitivity and prognosis in patients with ovarian cancer. Method HE4 and CA125 value …

Background Epithelial ovarian cancer (EOC) remains the main cause of mortality due to
gynecological malignancies. Optimal tumor debulking and platinum response are the most …

Objectives The aim of this study is to assess whether the pretreatment serum HE4 levels or
the Risk of Ovarian Malignancy Algorithm (ROMA) scores at the time of initial diagnosis are …

Objective The aim of this review was to analyze the state of the art about HE4 and follow-up
in patients treated for ovarian cancer. Methods A literature search was conducted in the …

HE4 is a commonly used tumor marker for ovarian cancer (OC) diagnosis. In our study, we
aimed to assess its use in the diagnosis of subsequent OC recurrences and to evaluate its …